Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

Study of GBHN Order Set project reveals improvements in the length of stay and ordering of best practices

A study of the Grey Bruce Health Network (GBHN) Order Set project has revealed impressive improvements in the length of stay and ordering of best practices.

13 Nov 2009

Third-quarter 2009 results announced by Response Biomedical

Response Biomedical Corporation today announced financial results for the third quarter and nine months ended September 30, 2009.

10 Nov 2009

Average cost of patient deaths much higher than patients who were discharged alive

One of every three people who died in 2007 in the United States were in the hospital for treatment at the time of their deaths, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. The cost of their hospital stays was about $20 billion.

6 Nov 2009

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2009.

3 Nov 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

Nonin Medical receives Medical Technology Award for Onyx II, Model 9560

Nonin Medical, Inc., a leading innovator of noninvasive physiological monitoring solutions, was awarded the Medical Technology Award and its owner and CTO, Phil Isaacson received the Technology Executive of the Year by the Minnesota High Tech Association (MHTA), in partnership with Enterprise Minnesota and LifeScience Alley.

30 Oct 2009

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that patient enrolment has begun for the ACT 5 trial, a confirmatory Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection, a drug product candidate under development for the rapid conversion of atrial fibrillation to sinus rhythm.

29 Oct 2009

NeoChord commences patient enrollment in its TACT European clinical trial

NeoChord, Inc., a venture-backed, Minneapolis-based medical technology company, announced today that it has enrolled the first patient in its European clinical trial. The trial, known as TACT (transapical artificial chordae tendineae) is being conducted in Germany, Denmark, Czech Republic and Norway.

28 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

NovaDel Pharma Inc., has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist® lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris.

28 Oct 2009

Hyperion Therapeutics enrolls first patient in HPN-100 phase III clinical trial for urea cycle disorders

Hyperion Therapeutics today announced that the first patient has been enrolled in its pivotal phase III clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The 4-week, multi-center, randomized, double-blind, cross-over study is designed to evaluate the non-inferiority of glycerol phenylbutyrate to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder in adults with urea cycle disorders.

27 Oct 2009

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

27 Oct 2009

Canadian cardiologists, oncologists team up to fight breast cancer

A team of Canadian cardiologists, in collaboration with oncologists, are playing an important role in the war against breast cancer Dr. Michael McDonald told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

26 Oct 2009

FDA grants IDE approval to Harvest Technologies to commence its BMAC Enhanced CABG trial

Harvest Technologies Corp. (www.harvesttech.com) announced today that the Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to commence its BMAC Enhanced CABG Trial. This is a two phase 42-patient 'feasibility' clinical trial using the company's BMAC System to concentrate autologous bone marrow cells to treat patients with congestive heart failure undergoing treatment with coronary artery bypass grafting (CABG) Surgery.

22 Oct 2009

FDA grants Response Biomedical a Special 510(k) clearance for the RAMP Influenza A/B Assay

Response Biomedical Corporation announced that the Company has been granted a Special 510(k) U.S. FDA clearance for an update to the Company’s RAMP® Influenza A/B Assay Package Insert to include analytical reactivity information for a strain of the 2009 H1N1 virus cultured from positive respiratory specimens.

22 Oct 2009

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Cell Therapeutics, Inc. announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients.

22 Oct 2009

Lake Health opens TriPoint Medical Center in Concord Township

Lake Health, formerly Lake Hospital System, today is celebrating the grand opening of its $155 million TriPoint Medical Center in Concord Township. A state-of-the-art digital hospital, TriPoint Medical Center is redefining the health care experience for patients, families and the community.

22 Oct 2009

APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Chlorothiazide Sodium for Injection, USP. APP expects to launch Chlorothiazide Sodium for Injection, USP in the fourth quarter of 2009.

21 Oct 2009

St. Jude Medical's quadripolar pacing system receives European CE Mark approval

St. Jude Medical, Inc. today announced it has received European CE Mark approval for the industry’s first quadripolar pacing system for cardiac resynchronization therapy defibrillators (CRT-Ds). The quadripolar system offers physicians the ability to more effectively and efficiently manage the ever-changing pacing needs of patients with heart failure.

21 Oct 2009

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.

20 Oct 2009

Congestive Heart Failure News and Research

Study of GBHN Order Set project reveals improvements in the length of stay and ordering of best practices

Third-quarter 2009 results announced by Response Biomedical

Average cost of patient deaths much higher than patients who were discharged alive

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Amgen publishes Phase 3 study results of Aranesp

Nonin Medical receives Medical Technology Award for Onyx II, Model 9560

Cardiome Pharmam, Astellas Pharma begin patient enrolment for ACT 5 trial

NeoChord commences patient enrollment in its TACT European clinical trial

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

Hyperion Therapeutics enrolls first patient in HPN-100 phase III clinical trial for urea cycle disorders

New data from efficacy study of CIMZIA in Crohn's disease patients presented

Canadian cardiologists, oncologists team up to fight breast cancer

FDA grants IDE approval to Harvest Technologies to commence its BMAC Enhanced CABG trial

FDA grants Response Biomedical a Special 510(k) clearance for the RAMP Influenza A/B Assay

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Lake Health opens TriPoint Medical Center in Concord Township

APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection

St. Jude Medical's quadripolar pacing system receives European CE Mark approval

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News